Medical Device Safety: India’s Perspective

Slides:



Advertisements
Similar presentations
Overview of Risk management: A EU perspective Lincoln Tsang May 2008.
Advertisements

Improving how your organisation supports the use of research evidence to inform policymaking.
NICE and NICE’s equality programme in 2012 Nick Doyle Clinical and public health analyst.
The Community Child Protection Programme The Community Child Protection Programme is a formal forum set up on a district wise basis as well as at grassroots.
IPhVWP Polish Presidency, Warsaw October 6 th 2011 Almath Spooner Irish Medicines Board Monitoring the outcome of risk minimisation activities.
by Joint Commission International (JCI)
Emergency Management Information System - EMIS
Module 3. Session DCST Clinical governance
Pharmacovigilance Programme of India
Ensuring Food Safety in Europe through Scientific Cooperation and Networking The Role of EFSA Carola Sondermann EFSA Polish Focal Point – Annual Experts.
1 Understanding CQC registration Summer Introduction to CQC.
Registering the care sector – next steps Dr Linda Hutchinson Director, Care Quality Commission National Care Association Conference, 21 October 2010.
FORMATION AND FUNCTIONING OF INDIAN PHARMACOPOEIA COMMISSION (IPC) By Dr G N Singh Member-Secretary.
Linking the learning to the National Standards for Safer Better Healthcare Joan Heffernan Inspector Manager Regulation – Healthcare Health Information.
FDA job description  Regulates about 25% of all consumer purchases  Mission summary: protect and advance public health  Products: food, cosmetics, drugs,
European Patients’ Academy on Therapeutic Innovation Introduction to pharmacovigilance Monitoring the safety of medicines.
Component 1: Introduction to Health Care and Public Health in the U.S. 1.9: Unit 9: The evolution and reform of healthcare in the US 1.9c: Quality Indicators.
1 PHARMACOVIGILANCE & THE NATIONAL ADVERSE DRUG REACTION (ADR) REPORTING SYSTEM Sarah Spiteri Post-Licensing Directorate Medicines Authority.
Towards Effective Climate Finance in LAC Caribbean Community Climate Change Centre.
RAC Regulatory Affairs Certification
CQC’s approach to inspection and regulation of General Practitioners
Off-label Use.
Knowledge for Healthcare: Driver Diagrams October 2016
A capacity building programme for patient representatives
Principles of Risk Management
health promotion and prevention of NCDs in community settings
Regulation of Medical Devices: Importance of a Globally Harmonized Approach Nicole Taylor Smith, JD September 2017.
IPHA Switch-on to Self-Care From Primary Care to Self-Care
Unit for Medical Systems and Devices at Ministry of Health
PHARMACIST : A HEALTH CARE PROFESSIONAL
Training structure EFFO Ebola Safety and good quality work
Purpose and Process of WHO guideline development
Critical Care Services Pharmacist Royal Manchester Children’s Hospital
Risk Communication in Medicines
EudraVigilance.
Reasonable Assurance of Safety and Effectiveness: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division.
Klaus Deininger, Nizalov Denys, Wael Zakout, Kathrine Kelm
Within Trial Decisions: Unblinding and Termination
Clinical Study Results Publication
Medical Device Regulatory Essentials: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.
Learning Aim B: Examine the ethical issues when Providing care and support to meet the individual needs. B1 & B2.
9. Introduction to signal detection
Access Equity in Prisons in Africa A CALL FOR ACTION
HUMAN RESEARCH PROTECTION PROGRAM or
Pharmacovigilance in Uganda
Helen Lee, European Commission
Electronic Health Information Systems
Improving Meal Time Processes
Christine Halleux, MD, PhD
Role & Relevance of Cochrane UK to trainees
AGREEMENT FOR TRANSPARENCY The Case of Mexico
Data sharing practices in the region
Commission strategy to
Medicines Safety Mary R. Couper
National Cancer Center
Plan your journey.
Pharmaceutical Industry Feedback HPRA Performance
2.1. Monitoring of products placed on the market To verify the products comply with applicable directives EC declaration of conformity and technical.
Tobey Clark, Director*, Burlington USA
Vigilance of medical devices and IVDs in the South East Asia Region –Safety Monitoring Systems in India and other Countries Dr. Madhur Gupta; MD, DM Technical.
Addressing decade long non-compliance of radiation safety in public health facilities of India Er. Ajai Basil Consultant, Healthcare Technologies (
Overview of the GMC’s Health and Wellbeing Programme
Head of Corporate Governance/ Board Secretary
Code of Ethics for CDM Professionals
Arthritis and Musculoskeletal Alliance
Code of Ethics for CDM Professionals
The National Data Guardian review & Government response
Getting Knowledge into Action for Healthcare Quality
Joint Action on Market Surveillance of medical devices (JAMS)
Accessible Information Provision for Lifelong Learning
Presentation transcript:

Medical Device Safety: India’s Perspective Ritu Jain, V. Kalaiselvan, A. Pramod Kumar Materiovigilance Programme of India Indian Pharmacopoeia Commission, Ghaziabad-570015, U.P, India 2  Poster Number: 31 What is the scope of Materiovigilance Programme of India?   MvPI came into existence to create a nation-wide system for patient safety monitoring. Analyse the benefit-risk ratio of medical devices, generate evidence-based information on safety of medical devices, support Central Drugs Standards Control Organization (CDSCO) in the decision-making process on use of medical devices. Communicate the safety information on use of medical devices to various stakeholders to minimise the risk, emerge as a national centre of excellence for Materiovigilance activities. Collaborate with other healthcare organisations for exchange of information and data management. Materiovigilance means close monitoring of any undesirable performance or characteristic fluctuations of a medical device by means of a system which is capable of identifying, collecting, reporting with estimate of undesirable occurrences and reacting to them with field safety corrective actions or device recall during post -marketing phase of a Medical Device. Ministry of Health and Family Welfare, Government of India has approved the commencement of “Materiovigilance Programme of India (MvPI)" with Indian Pharmacopoeia Commission, Ghaziabad. The National Coordinating Centre-MvPI to monitor the safety of medical devices in the country was formally launched on July 6, 2015 at Indian Pharmacopoeia Commission (IPC), Ghaziabad by The Drugs Controller General (India). The programme also aims to create awareness among healthcare professionals and others about the importance of Medical Device Adverse Event (MDAE) reporting and to monitor the benefit-risk profile of medical devices. MvPI authoritatively generate independent, evidence-based recommendations on the safety of medical devices and to communicate the findings to all key stakeholders. Mission of Materiovigilance Programme of India: Safeguard the health of Indian population by ensuring that the benefits of use of Medical Devices outweigh the risks associated with its use.  Objective of Materiovigilance Programme of India: To improve the protection of the health and safety of patients, healthcare professionals and others by reducing the likelihood reoccurrence of an adverse event associated with the use of Medical Devices. No medical device is completely devoid of risk. Therefore, it is essential to have a monitoring system to ensure patients and users safety. Disclosure : Authors declare no conflicts of interest.